Valeria S.

Addresses Alzheimer’s disease, agitation, psychosis, Major Depressive Disorder, and Schizophrenia.

• Adjunctive therapy for agitation associated with Alzheimer’s disease
• Safety and tolerability of KarXT for Alzheimer’s‑related psychosis
• Adjunctive treatment strategies for Major Depressive Disorder with anhedonia
• Novel agents for hallucinations and delusions in Alzheimer’s disease psychosis
• Behavioral symptom improvement in schizophrenia

Targets cognitive and behavioral symptoms across neurodegenerative and mood disorders.

Specializes in Crohn's disease and ulcerative colitis.

• Induction and maintenance of clinical remission in Crohn's disease
• Endoscopic response assessment in ulcerative colitis
• Combination therapy with guselkumab and golimumab for ulcerative colitis
• Dose‑finding studies of novel agents in moderate‑to‑severe ulcerative colitis
• Long‑term safety of oral etrasimod in Crohn's disease

Explores biologic and small‑molecule treatments to achieve mucosal healing.

Focuses on Atopic Dermatitis and Plaque Psoriasis.

• Upadacitinib efficacy in moderate‑to‑severe Atopic Dermatitis
• Combination of upadacitinib with topical corticosteroids for Atopic Dermatitis
• Long‑term safety of upadacitinib in Atopic Dermatitis
• JNJ‑77242113 efficacy in moderate‑to‑severe Plaque Psoriasis
• LY4100511 dose‑response in Plaque Psoriasis

Investigates targeted immunomodulators for chronic skin inflammation.

Engages with Atrial fibrillation, heart failure, atherosclerotic cardiovascular disease, and obesity.

• Non‑inferiority of milvexian compared with apixaban for stroke prevention
• Abelacimab efficacy in high‑risk atrial fibrillation patients
• Maridebart cafraglutide impact on cardiovascular morbidity and mortality
• NT‑proBNP reduction with tovinontrine in heart failure with preserved ejection fraction
• Weight‑related outcomes in atherosclerotic cardiovascular disease

Focuses on antithrombotic, heart failure, and metabolic interventions to reduce cardiovascular risk.